Philadelphia Trust Co. Makes New Investment in Moderna, Inc. $MRNA

Philadelphia Trust Co. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the third quarter, Holdings Channel reports. The fund bought 2,130 shares of the company’s stock, valued at approximately $410,000.

Several other hedge funds have also modified their holdings of MRNA. Western Pacific Wealth Management LP acquired a new position in shares of Moderna in the 3rd quarter valued at $29,000. Next Level Wealth Planning LLC acquired a new stake in Moderna during the 3rd quarter worth about $34,000. Ramsey Quantitative Systems acquired a new stake in Moderna during the 3rd quarter worth about $40,000. Fortitude Family Office LLC raised its holdings in Moderna by 53.1% during the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after buying an additional 77 shares during the period. Finally, MADDEN SECURITIES Corp acquired a new stake in Moderna during the 3rd quarter worth about $55,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Wall Street Analyst Weigh In

Several brokerages have commented on MRNA. William Blair cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 27th. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a report on Friday, August 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft started coverage on shares of Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $113.75.

Insider Transactions at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last three months. 10.80% of the stock is owned by corporate insiders.

Moderna Stock Down 6.8%

Shares of Moderna stock opened at $250.83 on Wednesday. The stock has a 50-day moving average price of $196.68 and a 200 day moving average price of $93.60. The company has a market cap of $101.49 billion, a P/E ratio of -35.33 and a beta of 1.16. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same period last year, the company posted ($0.51) EPS. The business’s quarterly revenue was up 29.2% compared to the same quarter last year. As a group, analysts expect that Moderna, Inc. will post -5.69 EPS for the current fiscal year.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.